

Earlier this year, as part of Vice President Biden’s Cancer Moonshot initiative, the White House established a Blue Ribbon Panel of experts to report on the current challenges and opportunities facing cancer research.
In this CAC2 Research Interest Group webinar for September1 2016, CAC2 welcomed Blue Ribbon Panel members Dr. Peter Adamson (Chair of the Children’s Oncology Group) and David Arons (CEO of the National Brain Tumor Society) in a discussion of the panel’s recently issued report and its implications for pediatric cancer.
Categories
- Blog Posts (124)
- Explainer Post (12)
- Guest Blogs (33)
- Member Blogs (44)
- Survivorship Matters Blog (9)
- CAC2 News (23)
- Collaborative Achievements (15)
- Community News (276)
- In Memoriam (2)
- News Digest (225)
- Webinars (66)
Tags
Advocacy (58)
Annual Summit (7)
Appropriations (1)
Awareness (26)
AYA (2)
Bereavement (1)
Best Practices (14)
Biorepositories (2)
CAC2 News (8)
CAC2 Projects (11)
Call to Action (27)
Call to Action Prevention (1)
Care Giving (1)
Clinical Trials (11)
COG (2)
Collaboration (14)
Data (16)
Delayed Diagnosis (2)
Digest (12)
Drug Development (15)
Drug Development collaboration (1)
Drug Shortages (3)
Ethics (1)
Family Support (17)
FDA (2)
Funding Research (9)
Genomics (6)
Global News (4)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (2)
Post-Mortem Tissue Donation (1)
Prevention (3)
Psychosocial Support (6)
Rare and Ultra Rare Cancer (1)
Regulations (3)
Research (41)
Research Advocacy (3)
Research Data (2)
Research Tissue Donation (1)
Social Work (1)
state advocacy (1)
Survivorship (30)
Venture Philanthropy (3)
Recent Posts
- CAC2 Webinar–“Patient Advocacy, Non-Profit Foundations, and the Changing Landscape of Pediatric Cancer Funding”
- Guest Blog–Applications Open: 2025 HBF Inspiration Award for Early Career Investigators in Pediatric Brain Cancer
- CAC2 Childhood Cancer Community News Digest (April 21-27)
- CAC2 Childhood Cancer Community News Digest (April 14-20)
- CAC2 Webinar–“The Role of AI from Diagnosis to Treatment for Childhood Cancer”